A late-stage trial showed Eli Lilly and Co.'s experimental drug ramucirumab, in combination with docetaxel, significantly improved survival and progression-free survival in patients with non-small cell lung cancer compared with a combination of placebo and docetaxel. Eli Lilly plans to submit the drug for regulatory review for this indication later this year. Ramucirumab is also under development for treatment of liver cancer and colorectal cancer.

Full Story:

Related Summaries